Recent progress of aptamer-drug conjugates in cancer therapy  

作　　者：Jiaxuan He Qiao Duan Chunyan Ran Ting Fu Yuan Liu Weihong Tan 

机构地区：[1]The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),The Key Laboratory of Zhejiang Province for Aptamers and Theranostics,Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou 310022,China [2]Molecular Science and Biomedicine Laboratory(MBL),State Key Laboratory of Chemo/Biosensing and Chemometrics,College of Chemistry and Chemical Engineering,College of Biology,Aptamer Engineering Center of Hunan Province,Hunan University,Changsha 410082,China [3]Institute of Molecular Medicine(IMM),Renji Hospital,Shanghai Jiao Tong University School of Medicine,and College of Chemistry and Chemical Engineering,Shanghai Jiao Tong University,Shanghai 200240,China

出　　处：《Acta Pharmaceutica Sinica B》2023年第4期1358-1370,共13页药学学报（英文版）

基　　金：supported by the Zhejiang Provincial Natural Science Foundation of China(No.Y21C050001,China);Zhejiang Provincial Research Center for Diagnosis and Treatment of Major Diseases(No.JBZX-202003,China);the National Natural Science Foundation of China(Nos.22104132 and 22204144);the Zhejiang Province“Kunpeng”Program;。

摘　　要：Aptamers are single-stranded DNA or RNA sequences that can specifically bind with the target protein or molecule via specific secondary structures.Compared to antibody-drug conjugates(ADC),aptamer-drug conjugate(ApDC)is also an efficient,targeted drug for cancer therapy with a smaller size,higher chemical stability,lower immunogenicity,faster tissue penetration,and facile engineering.Despite all these advantages,several key factors have delayed the clinical translation of ApDC,such as in vivo off-target effects and potential safety issues.In this review,we highlight the most recent progress in the development of ApDC and discuss solutions to the problems noted above.

关 键 词：APTAMER Cancer therapy Aptamer-drug conjugate Drug delivery Small-molecule drug Therapeutic molecules Nucleic acid drugs Biotherapeutic drug 

分 类 号：R730.5[医药卫生—肿瘤]